Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA?
{{output}}
The interleukin 6 receptor antagonist tocilizumab was investigated in a 24-week, phase III randomized controlled trial for the treatment of active, DMARD-resistant rheumatoid arthritis (TOWARD study). The results indicated that the combination of tocilizumab w... ...
